2018 Oral Mucositis Drug Development – Pipeline Analysis – ResearchAndMarkets.com

The “2018
Oral Mucositis Drug Development- Pipeline Analysis Report”
report has been added to ResearchAndMarkets.com’s
offering.

With an estimated $2 billion market value, the Oral Mucositis disease
pipeline presents strong opportunities for development of treatment
options. Absence of preventive or curative treatment for the Oral
Mucositis is encouraging investigators in major companies to focus on
pipeline. Further, an increasing trend towards grant announcements is
being observed in the segment.

The disease occurs primarily as a result of damage to epithelium by
chemoradiation.

The report provides insights into different therapeutic candidates in
preclinical, research, discovery, NDA/IND, pre registration, phase 1,
phase 2, and phase 3 trials). Drugs under development directly and
through combination with other drugs are also included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Oral Mucositis pipeline
product. Mechanism of Action and the target area of the pipeline product
are also provided. Further, clinical and preclinical trials along with
results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Oral Mucositis pipeline studies. The products under
development are categorized according to their development phase,
mechanism and company to provide detailed insights into the type of
drugs being developed and the stages of development.

Key Topics Covered:

1 Oral Mucositis Pipeline Analysis

2 Oral Mucositis – Company Wise Pipeline Analysis

3 Oral Mucositis R&D Pipeline Snapshots

4 Recent Developments in Oral Mucositis Pipeline

5 Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/research/69j9kb/2018_oral?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005463/en/

Leave a Comment